Aktis Oncology (NASDAQ:AKTS) Receives $34.00 Average PT from Analysts

Shares of Aktis Oncology (NASDAQ:AKTS) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $34.00.

Several analysts recently weighed in on AKTS shares. Weiss Ratings lowered Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, June 9th. Raymond James Financial started coverage on Aktis Oncology in a report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target on the stock. HC Wainwright increased their price target on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Finally, William Blair started coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock.

Aktis Oncology Stock Performance

Shares of AKTS opened at $27.01 on Wednesday. The business’s 50 day moving average price is $20.17. Aktis Oncology has a 1 year low of $14.72 and a 1 year high of $29.16.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The company had revenue of $1.87 million during the quarter. As a group, equities analysts forecast that Aktis Oncology will post -1.62 EPS for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.